192 related articles for article (PubMed ID: 26109523)
1. Dose finding with longitudinal data: simpler models, richer outcomes.
Paoletti X; Doussau A; Ezzalfani M; Rizzo E; Thiébaut R
Stat Med; 2015 Sep; 34(22):2983-98. PubMed ID: 26109523
[TBL] [Abstract][Full Text] [Related]
2. Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials.
Doussau A; Thiébaut R; Paoletti X
Stat Med; 2013 Dec; 32(30):5430-47. PubMed ID: 24018535
[TBL] [Abstract][Full Text] [Related]
3. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
[TBL] [Abstract][Full Text] [Related]
4. Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology.
Colin P; Micallef S; Delattre M; Mancini P; Parent E
Stat Med; 2015 Sep; 34(22):2999-3016. PubMed ID: 26059319
[TBL] [Abstract][Full Text] [Related]
5. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials.
Hirakawa A
Stat Med; 2012 Mar; 31(6):516-32. PubMed ID: 22108785
[TBL] [Abstract][Full Text] [Related]
6. A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.
Yin J; Qin R; Ezzalfani M; Sargent DJ; Mandrekar SJ
Stat Med; 2017 Jan; 36(1):67-80. PubMed ID: 27633877
[TBL] [Abstract][Full Text] [Related]
7. A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.
Zang Y; Lee JJ
Stat Med; 2017 Jan; 36(1):27-42. PubMed ID: 27538818
[TBL] [Abstract][Full Text] [Related]
8. Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method.
Van Meter EM; Garrett-Mayer E; Bandyopadhyay D
Clin Trials; 2012 Jun; 9(3):303-13. PubMed ID: 22547420
[TBL] [Abstract][Full Text] [Related]
9. Bridging continual reassessment method for phase I clinical trials in different ethnic populations.
Liu S; Pan H; Xia J; Huang Q; Yuan Y
Stat Med; 2015 May; 34(10):1681-94. PubMed ID: 25626429
[TBL] [Abstract][Full Text] [Related]
10. Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.
Muenz DG; Braun TM; Taylor JM
Clin Trials; 2018 Aug; 15(4):386-397. PubMed ID: 29779418
[TBL] [Abstract][Full Text] [Related]
11. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
Paoletti X; Kramar A
Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
[TBL] [Abstract][Full Text] [Related]
12. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
Du Y; Yin J; Sargent DJ; Mandrekar SJ
J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
[TBL] [Abstract][Full Text] [Related]
13. Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.
Wages NA; Tait C
J Biopharm Stat; 2015; 25(5):903-20. PubMed ID: 24904956
[TBL] [Abstract][Full Text] [Related]
14. Improved adaptive randomization strategies for a seamless Phase I/II dose-finding design.
Yan D; Wages NA; Dressler EV
J Biopharm Stat; 2019; 29(2):333-347. PubMed ID: 30451068
[TBL] [Abstract][Full Text] [Related]
15. Dose finding with continuous outcome in phase I oncology trials.
Wang Y; Ivanova A
Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518
[TBL] [Abstract][Full Text] [Related]
16. Bayesian model averaging continual reassessment method for bivariate binary efficacy and toxicity outcomes in phase I oncology trials.
Asakawa T; Hirakawa A; Hamada C
J Biopharm Stat; 2014; 24(2):310-25. PubMed ID: 24605971
[TBL] [Abstract][Full Text] [Related]
17. Efficacy/toxicity dose-finding using hierarchical modeling for multiple populations.
Cunanan KM; Koopmeiners JS
Contemp Clin Trials; 2018 Aug; 71():162-172. PubMed ID: 29936124
[TBL] [Abstract][Full Text] [Related]
18. Three-dose-cohort designs in cancer phase I trials.
Huang B; Chappell R
Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
[TBL] [Abstract][Full Text] [Related]
19. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
20. A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials.
Doussau A; Thiébaut R; Geoerger B; Schöffski P; Floquet A; Le Deley MC; Mathoulin-Pélissier S; Rizzo E; Fumoleau P; Le Tourneau C; Paoletti X
Ann Oncol; 2015 Feb; 26(2):422-8. PubMed ID: 25403589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
